PROPANC BIOPHARMA, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PROPANC BIOPHARMA, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-12-31 was $115.08K, a 97.47% increase year-over-year.
- PROPANC BIOPHARMA, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-09-30 was $438.06K, a 338.54% increase year-over-year.
- PROPANC BIOPHARMA, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-03-31 was $18.20K, a 90.67% decline year-over-year.
- PROPANC BIOPHARMA, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-12-31 was $58.28K, a 36.69% decline year-over-year.
- PROPANC BIOPHARMA, INC. stock issued during period, value, conversion of convertible securities for fiscal 2023 was $1.39M, a 111.18% increase from fiscal 2022.
- PROPANC BIOPHARMA, INC. stock issued during period, value, conversion of convertible securities for fiscal 2022 was $657.13K, a 46.97% decline from fiscal 2021.
- PROPANC BIOPHARMA, INC. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $1.24M, a 41.70% decline from fiscal 2020.
- PROPANC BIOPHARMA, INC. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $2.13M, a 36.58% decline from fiscal 2019.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2025-12-31 | $115.08K S-1 · filed 2026-07-17 | |
| 2025-09-30 | $438.06K S-1 · filed 2026-07-17 | |
| 2025-06-30 | $176.38K S-1 · filed 2026-07-17 | |
| 2025-03-31 | $18.20K S-1 · filed 2026-07-17 | |
| 2024-12-31 | $58.28K S-1 · filed 2026-07-17 | |
| 2024-09-30 | $99.89K S-1 · filed 2026-07-17 | |
| 2024-06-30 | $773.55K S-1 · filed 2026-07-17 | |
| 2024-03-31 | $195.09K 10-Q · filed 2025-05-15 | |
| 2023-12-31 | $92.06K 10-Q · filed 2025-05-15 | |
| 2023-09-30 | $229.19K 10-Q · filed 2025-05-15 | |
| 2023-06-30 | $1.39M 10-K · filed 2024-09-30 | |
| 2023-03-31 | $435.20K 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $165.69K 10-Q · filed 2024-05-15 | |
| 2022-09-30 | $456.94K 10-Q · filed 2024-05-15 | |
| 2022-06-30 | $657.13K 10-K · filed 2023-09-28 | |
| 2022-03-31 | $189.97K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $26.73K 10-Q · filed 2023-05-15 | |
| 2021-09-30 | $200.19K 10-Q · filed 2023-05-15 | |
| 2021-06-30 | $1.24M 10-K · filed 2022-09-28 | |
| 2021-03-31 | $391.80K 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $141.83K 10-Q · filed 2022-05-16 | |
| 2020-09-30 | $480.57K 10-Q · filed 2022-05-16 | |
| 2020-06-30 | $2.13M 10-K · filed 2021-09-28 | |
| 2020-03-31 | $810.09K 10-Q · filed 2021-05-14 | |
| 2019-12-31 | $219.47K 10-Q · filed 2021-05-14 | |
| 2019-09-30 | $123.71K 10-Q · filed 2021-05-14 | |
| 2019-06-30 | $3.35M 10-K · filed 2020-10-01 | |
| 2019-03-31 | $583.33K 10-Q · filed 2020-05-15 | |
| 2018-12-31 | $1.10M 10-Q · filed 2020-05-15 | |
| 2018-09-30 | $1.41M 10-Q · filed 2020-05-15 | |
| 2018-06-30 | $2.77M 10-K · filed 2019-10-15 | |
| 2018-03-31 | $988.82K 10-Q · filed 2019-05-15 | |
| 2017-12-31 | $893.42K 10-Q · filed 2019-05-15 | |
| 2017-09-30 | $484.51K 10-Q · filed 2019-05-15 | |
| 2017-06-30 | $1.41M 10-K · filed 2018-09-17 | |
| 2016-06-30 | $4.90M 10-K · filed 2017-09-28 | |
| 2015-06-30 | $441.16K 10-K · filed 2016-09-28 | |
| 2013-06-30 | $76.90K 10-K · filed 2014-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |